RECURRENT CANCER
Clinical trials for RECURRENT CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CANCER trials appear
Sign up with your email to follow new studies for RECURRENT CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests a new drug called CYH33 in 93 women whose ovarian, fallopian tube, or peritoneal clear cell cancer has returned or not gone away. The drug targets a specific genetic change (PIK3CA mutation) to try to shrink tumors. Participants must have already tried standard c…
Matched conditions: RECURRENT CANCER
Phase: PHASE2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Nanoparticle-Proton combo for recurrent cancer study pulled before start
Disease control TerminatedThis study aimed to test a new treatment for people whose cancer returned after previous radiation therapy. The approach combined special nanoparticles injected into the blood with targeted proton therapy to try to control the tumor. The study was withdrawn before any participant…
Matched conditions: RECURRENT CANCER
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New immune drug IMA401 takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug called IMA401 in about 95 adults with advanced solid tumors (like lung or head/neck cancer) that came back or didn't respond to prior treatments. IMA401 is a special immune molecule that helps the body's T cells attack cancer cells. The stu…
Matched conditions: RECURRENT CANCER
Phase: PHASE1 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated May 18, 2026 12:09 UTC